.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
McKinsey
Colorcon
Federal Trade Commission
Covington
Fuji
Cantor Fitzgerald
Novartis
Medtronic
Julphar

Generated: June 26, 2017

DrugPatentWatch Database Preview

AURYXIA Drug Profile

« Back to Dashboard

What is the patent landscape for Auryxia, and when can generic versions of Auryxia launch?

Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. There are thirteen patents protecting this drug.

This drug has one hundred and seven patent family members in twenty-five countries.

The generic ingredient in AURYXIA is ferric citrate. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric citrate profile page.

Summary for Tradename: AURYXIA

Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list27
Clinical Trials: see list5
Patent Applications: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AURYXIA at DailyMed

Pharmacology for Tradename: AURYXIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes8,299,298► SubscribeY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes9,328,133► SubscribeYY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes9,387,191► SubscribeY ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes8,093,423► Subscribe ► Subscribe
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes8,901,349► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: AURYXIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 20145,753,706► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AURYXIA

Country Document Number Estimated Expiration
HungaryE025264► Subscribe
China101374416► Subscribe
Eurasian Patent Organization200501322► Subscribe
Canada2640974► Subscribe
Russian Federation2563819► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Deloitte
Farmers Insurance
US Army
McKesson
Covington
Medtronic
Novartis
Cantor Fitzgerald
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot